keyword
MENU ▼
Read by QxMD icon Read
search

Viral and fibrosis

keyword
https://www.readbyqxmd.com/read/29332571/role-of-heart-rate-reduction-in-the-management-of-myocarditis
#1
Chen Guang-Yi, Ge Li-Sha, Li Yue-Chun
The morbidity of myocarditis demonstrates an upward tendency by years, is commonly defined as the inflammation of myocytes and is caused by multiple factors. With the development of the molecular biological technique, great breakthroughs in the diagnosis and understanding of pathophysiological mechanisms of myocarditis have recently been achieved. Several questions remain unresolved, however, including standard treatment approaches to myocarditis, which remain controversial and ambiguous. Heart rate, as an independent risk factor, has been shown to be related to cardiac disease...
January 10, 2018: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/29330726/ultra-deep-genomic-sequencing-of-hcv-ns5a-resistance-associated-substitutions-in-hcv-hiv-coinfected-patients
#2
Enass A Abdel-Hameed, Susan D Rouster, Ceejay L Boyce, Xiang Zhang, Jacek Biesiada, Mario Medvedovic, Kenneth E Sherman
BACKGROUND AND AIMS: The prevalence of naturally occurring HCV-NS5A resistance-associated substitutions (RAS) to DAA drugs might affect the response to treatment in HCV/HIV coinfected subjects. There are limited data on the frequency of HCV-NS5A naturally occurring drug-RAS at baseline in HCV/HIV coinfected patients when ultra-deep sequencing methodologies are applied. METHODS: HCV-NS5A-RAS were evaluated among 25 subjects in each group. Patients were matched by age, gender, and hepatic fibrosis stage category to control for selection bias...
January 12, 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29329373/co-existing-hepatitis-c-and-alcoholic-liver-disease-a-diminishing-indication-for-liver-transplantation
#3
Amanda Wieland, Gregory T Everson
Aims: To provide an overview of published literature on the interaction of alcohol and hepatitis C virus (HCV) in the accelerated progression of liver disease to cirrhosis as relates to decision-making for the management of the liver transplant candidate and recipient. Methods: General PubMed search was employed along with expert input to identify the relevant articles on the topic. The authors also utilized both backward and forward citation review of the relevant articles and reviews to identify articles on identified topic...
January 10, 2018: Alcohol and Alcoholism: International Journal of the Medical Council on Alcoholism
https://www.readbyqxmd.com/read/29318378/mac-2-binding-protein-glycan-isomer-m2bpgi-is-a-new-serum-biomarker-for-assessing-liver-fibrosis-more-than-a-biomarker-of-liver-fibrosis
#4
REVIEW
Ken Shirabe, Yuki Bekki, Dolgormaa Gantumur, Kenichiro Araki, Norihiro Ishii, Atsushi Kuno, Hisashi Narimatsu, Masashi Mizokami
Assessing liver fibrosis is important for predicting the efficacy of antiviral therapy and patient prognosis. Liver biopsy is the gold standard for diagnosing liver fibrosis, despite its invasiveness and problematic diagnostic accuracy. Although noninvasive techniques to assess liver fibrosis are becoming important, reliable serum surrogate markers are not available. A glycoproteomics study aimed at identifying such markers discovered Mac 2-Binding Protein Gylcan Isomer (M2BPGi), which is a reliable marker for assessing liver fibrosis in patients with viral hepatitis and other fibrotic liver diseases such as primary biliary cholangitis, biliary atresia, autoimmune hepatitis, and nonalcoholic fatty liver disease...
January 9, 2018: Journal of Gastroenterology
https://www.readbyqxmd.com/read/29315085/biopsy-confirmed-endothelial-cell-activation-in-patients-with-coronary-microvascular-dysfunction
#5
Hannes Lindemann, Ivana Petrovic, Stephan Hill, Anastasios Athanasiadis, Heiko Mahrholdt, Tim Schäufele, Karin Klingel, Udo Sechtem, Peter Ong
BACKGROUND: Patients with angina yet having unobstructed coronaries are found in ∼50% of cases undergoing invasive angiography. Coronary spasm and microvascular dysfunction can be responsible for the clinical presentation in ∼60% of cases. However, little is known about structural changes in the myocardium. The aim of this study was to describe findings in endomyocardial biopsies of symptomatic patients with unobstructed coronaries. PATIENTS AND METHODS: We retrospectively analyzed a cohort of 1416 consecutive patients who underwent endomyocardial biopsy sampling and coronary angiography between 2002 and 2016 for various clinical indications...
January 8, 2018: Coronary Artery Disease
https://www.readbyqxmd.com/read/29314465/sequential-therapy-involving-an-early-switch-from-entecavir-to-pegylated-interferon-%C3%AE-in-japanese-patients-with-chronic-hepatitis-b
#6
Masaru Enomoto, Shuhei Nishiguchi, Akihiro Tamori, Ritsuzo Kozuka, Hideki Fujii, Sawako Uchida-Kobayashi, Shinya Fukunishi, Yasuhiro Tsuda, Kazuhide Higuchi, Masaki Saito, Hirayuki Enomoto, Norifumi Kawada
AIM: The optimal combination of the two currently available agents with different mechanisms of action, a nucleos(t)ide analog and pegylated interferon-α (PegIFNα), must be determined to improve treatment of chronic hepatitis B. METHODS: In this study, 24 patients with chronic hepatitis B (14 hepatitis B e-antigen [HBeAg]-positive and 10 HBeAg-negative) received entecavir for 36-52 weeks, followed by entecavir plus PegIFNα-2a for 4 weeks and finally by PegIFNα-2a alone for 44 weeks...
January 4, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29312858/de-novo-glomerular-diseases-after-renal-transplantation-how-is-it-different-from-recurrent-glomerular-diseases
#7
REVIEW
Fedaey Abbas, Mohsen El Kossi, Jon Kim Jin, Ajay Sharma, Ahmed Halawa
The glomerular diseases after renal transplantation can occur de novo, i.e., with no relation to the native kidney disease, or more frequently occur as a recurrence of the original disease in the native kidney. There may not be any difference in clinical features and histological pattern between de novo glomerular disease and recurrence of original glomerular disease. However, structural alterations in transplanted kidney add to dilemma in diagnosis. These changes in architecture of histopathology can happen due to: (1) exposure to the immunosuppression specifically the calcineurin inhibitors (CNI); (2) in vascular and tubulointerstitial alterations as a result of antibody mediated or cell-mediated immunological onslaught; (3) post-transplant viral infections; (4) ischemia-reperfusion injury; and (5) hyperfiltration injury...
December 24, 2017: World Journal of Transplantation
https://www.readbyqxmd.com/read/29299684/treatment-of-hepatitis-c-in-special-populations
#8
REVIEW
Goki Suda, Koji Ogawa, Kenichi Morikawa, Naoya Sakamoto
Hepatitis C virus (HCV) infection is one of the primary causes of liver cirrhosis and hepatocellular carcinoma. In hemodialysis patients, the rate of HCV infection is high and is moreover associated with a poor prognosis. In liver transplantation patients with HCV infection, recurrent HCV infection is universal, and re-infected HCV causes rapid progression of liver fibrosis and graft loss. Additionally, in patients with HCV and human immunodeficiency virus (HIV) co-infection, liver fibrosis progresses rapidly...
January 3, 2018: Journal of Gastroenterology
https://www.readbyqxmd.com/read/29290175/future-considerations-for-the-evaluation-of-hepatitis-c-virus-treatments-in-pan-genotypic-therapy-for-noncirrhotic-treatment-naive-patients
#9
Martin J Calabrese, Lauren M Hynicka, Magaly Rodriguez de Bittner, Fadia T Shaya
Given the recent approval of the first pan-genotypic chronic hepatitis C virus (HCV) therapy, managed care, health systems, and clinicians will need to evaluate current practices related to essential laboratory assessments used to select therapy. Historically, clinicians and payers required a battery of tests to determine HCV genotype, viral load, degree of fibrosis, and organ function. In light of current and forthcoming approvals of pan-genotypic therapy, clinicians and payers can expect a more competitive marketplace and a downward curve in the price of therapy...
January 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29290174/eight-week-outcomes-of-ledipasvir-sofosbuvir-in-noncirrhotic-treatment-naive-patients-with-hepatitis-c-analysis-of-pharmacy-based-data
#10
Jennifer Andres, Stephen Lott, Kamran Qureshi
BACKGROUND: Clinical trials have demonstrated that 8 weeks of ledipasvir and sofosbuvir (LDV/SOF) achieved high rates of sustained virologic response at 12 weeks (SVR12) in patients with hepatitis C viral (HCV) genotype 1 infection. The effectiveness of this combination was noted to be robust in treatment-naive noncirrhotic patients and in patients with an HCV viral load of < 6 million IU/mL before treatment. Generalizability of these results to community clinical practice, however, was advised with caution due to the variability of staging methods, fluctuating nature of viral loads, lack of prospective trials, and real-life confirmation...
January 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29288753/impact-of-comorbidities-on-patients-outcomes-after-interferon-free-therapy-induced-viral-eradication-in-hepatitis
#11
Javier Ampuero, Carlota Jimeno, Rosa Quiles, José Miguel Rosales, Susana Llerena, Nieves Palomo, Patricia Cordero, Francisco Javier Serrano, Juan José Urquijo, José María Moreno-Planas, Guillermo Ontanilla, Marta Hernández, Aída Ortega-Alonso, Marta Maraver, Martín Bonacci, Ángela Rojas, Blanca Figueruela, Xavier Forns, Raúl J Andrade, José Luis Calleja, Moisés Diago, Isabel Carmona, Manuel de la Mata, María Buti, Javier Crespo, Juan Manuel Pascasio, José María Navarro, Javier Salmerón, Manuel Romero-Gómez
BACKGROUND&AIMS: Patients with advanced liver fibrosis remain at risk of cirrhosis-related outcomes and those with severe comorbidities could not benefit from Hepatitis C (HCV) eradication. We aimed to collect all-cause mortality and relevant clinical events within the first two years in patients undergoing direct antiviral therapy and determine the impact of a comorbidity-based model on it. METHODS: This was a prospective non-interventional study, from the beginning of direct-acting antiviral therapy to the event of interest (mortality) or up to 2 years of follow-up, including 14 Spanish University Hospitals...
December 27, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29285064/predictors-for-advanced-liver-fibrosis-in-chronic-hepatitis-b-virus-infection-with-persistently-normal-or-mildly-elevated-alanine-aminotransferase
#12
Dexin Wang, Ping Zhang, Min Zhang
The aim of the present study was to evaluate the predictors for advanced liver fibrosis in patients with chronic hepatitis B virus (HBV) infection with persistently normal alanine aminotransferase (PNALT), or persistently or intermittently mildly elevated ALT (PIEALT). A total of 305 patients were included in the present study. Liver biopsies were evaluated using the METAVIR scoring system. Liver stiffness (LS) was measured using Fibroscan. Multivariate logistic regression and the area under the receiver operating characteristic curve (AUROC) were used to examine the diagnostic value of the predictors for advanced liver fibrosis...
December 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29281894/adeno-associated-virus-2-aav2-mediated-reintroduction-of-microrna-19b-attenuates-hepatic-fibrosis
#13
Elizabeth Brandon-Warner, Jennifer H Benbow, Jacob H Swet, Nicole A Feilen, Catherine R Culberson, Iain H McKillop, Andrew S deLemos, Mark W Russo, Laura W Schrum
Fibrotic liver injury is a significant healthcare burden in the United States that represents a major cause of morbidity and mortality for which there are no effective FDA approved treatment strategies. Fibrosis is considered a disruption of normal wound healing responses mediated by fibroblastic cells which are triggered and sustained by pro-fibrotic cytokines such as transforming growth factor-beta1 (TGFβ1). TGFβ1-mediated transdifferentiation of hepatic stellate cells (HSCs) from quiescent to activated myofibroblast is a pivotal event in the development of fibrosis...
December 27, 2017: Human Gene Therapy
https://www.readbyqxmd.com/read/29279304/the-banff-working-group-classification-of-definitive-polyomavirus-nephropathy-morphologic-definitions-and-clinical-correlations
#14
Volker Nickeleit, Harsharan K Singh, Parmjeet Randhawa, Cinthia B Drachenberg, Ramneesh Bhatnagar, Erika Bracamonte, Anthony Chang, W James Chon, Darshana Dadhania, Vicki G Davis, Helmut Hopfer, Michael J Mihatsch, John C Papadimitriou, Stefan Schaub, Michael B Stokes, Mohammad F Tungekar, Surya V Seshan
Polyomavirus nephropathy (PVN) is a common viral infection of renal allografts, with biopsy-proven incidence of approximately 5%. A generally accepted morphologic classification of definitive PVN that groups histologic changes, reflects clinical presentation, and facilitates comparative outcome analyses is lacking. Here, we report a morphologic classification scheme for definitive PVN from the Banff Working Group on Polyomavirus Nephropathy, comprising nine transplant centers in the United States and Europe...
December 26, 2017: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/29275953/translational-research-to-enable-personalized-treatment-of-cystic-fibrosis
#15
Marne C Hagemeijer, Daniel J Siegwart, Lisa J Strug, Liudmila Cebotaru, Michael J Torres, Aderonke Sofoluwe, Jeffrey M Beekman
Translational research efforts in cystic fibrosis (CF) aim to develop therapies for all subjects with CF. To reach this goal new therapies need to be developed that target multiple aspects of the disease. To enable individuals to benefit maximally from these treatments will require improved methods to tailor these therapies specifically to individuals who suffer from CF. This report highlights current examples of translational CF research efforts to reach this goal. The use of intestinal organoids and genetics to better understand individual assessment of CFTR modulator treatment effects to ultimately enable a better personalized treatment for CF subjects will be discussed...
December 21, 2017: Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society
https://www.readbyqxmd.com/read/29274193/efficacy-and-safety-of-6-or-8-weeks-of-simeprevir-daclatasvir-sofosbuvir-for-hcv-genotype-1-infection
#16
M S Sulkowski, J J Feld, E Lawitz, F Felizarta, A M Corregidor, O Khalid, R Ghalib, W B Smith, V Van Eygen, D Luo, L Vijgen, M Gamil, T N Kakuda, S Ouwerkerk-Mahadevan, P Van Remoortere, M Beumont
The phase 2, open-label ACCORDION (ClinicalTrials. gov: NCT02349048) study investigated the efficacy, safety and pharmacokinetics of a 6- or 8-week regimen of simeprevir, daclatasvir and sofosbuvir in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype (GT) 1 infection and either early-stage fibrosis or compensated cirrhosis. Patients were assigned to treatment groups according to their fibrosis stage. Early-stage fibrosis: simeprevir 150 mg, daclatasvir 60 mg, sofosbuvir 400 mg once daily for 6 weeks; compensated cirrhosis: same regimen for 8 weeks...
December 23, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29260741/-lymphocyte-subpopulations-levels-of-interferon-and-expression-of-their-receptors-in-patients-with-chronic-hepatitis-b-and-c-correlation-with-the-species-of-viruses-and-the-degree-of-liver-fibrosis
#17
O V Kalyuzhin, Zh B Ponezheva, I V Semenova, O N Khokhlova, L V Serebrovskaya, T S Guseva, O V Parshina, V V Maleev
AIM: To determine whether there is a correlation of the composition of circulating lymphocyte subpopulations, the serum concentrations of interferon (IFN)-α, IFN-γ, and IFN-λ3, and the lymphocyte expression of types I and II IFN receptors with the species of a disease pathogen and the degree of liver fibrosis (LF) in patients with chronic hepatitis B (CHB) and in those with chronic hepatitis C (CHC). SUBJECTS AND METHODS: The investigation enrolled 44 patients with CHC, 9 patients with CHB, and 13 clinically healthy donors...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/29235144/histological-assessment-of-the-liver-explant-in-transplanted-hcv-patients-achieving-sustained-virologic-response-with-direct-acting-antiviral-agents
#18
Juan Putra, Thomas D Schiano, M Isabel Fiel
AIMS: The use of direct-acting anti-viral agents (DAAs) has resulted in extremely high sustained virologic response (SVR) rates in patients being treated while on liver transplantation (LT) waiting lists. The aim of this study was to evaluate the histological findings of HCV patients who achieved SVR after receiving DAA treatment (SVR(+)) prior to LT and comparing them to HCV patients who had not achieved SVR (SVR(-)). METHODS AND RESULTS: Fifty-eight adult HCV patients who underwent LT at our institution from 2014-2016 were included in the study...
December 13, 2017: Histopathology
https://www.readbyqxmd.com/read/29234569/a-case-of-localized-pulmonary-calcification-presenting-as-a-persistent-mass-lesion-in-an-immunosuppressed-patient-following-treatment-of-a-pseudomonas-pneumonia
#19
Matthew J Cecchini, Dominic L Shepherd, Jessica G Shepherd
We report a case of a persistent right upper lobe opacity following treatment for a Pseudomonas infection in an immunosuppressed patient with a recent renal transplantation. The patient underwent a surgical lung biopsy for definitive diagnosis of the mass. The lesion was composed of extensive calcifications deposited throughout the lung with associated fibrosis. The patient had a history of a remote parathyroidectomy for hyperparathyroidism; however, the parathyroid hormone (PTH) and the calcium levels were still mildly elevated...
October 11, 2017: Curēus
https://www.readbyqxmd.com/read/29232404/antioxidant-antiapoptotic-and-amino-acid-balance-regulating-activities-of-1-7-dihydroxy-3-4-8-trimethoxyxanthone-against-dimethylnitrosamine-induced-liver-fibrosis
#20
Xi-Yuan Zheng, Xin Zhao, Ying-Fan Yang, Han-Jie Jiang, Wan Li, Yi Sun, Xiao-Ping Pu
Liver fibrosis represents the consequences of a sustained wound healing response to chronic liver injury which could be caused by viral, autoimmune, drugs, and so on. Unfortunately, there was no effective therapy available for liver fibrosis in clinic. In this study, we identified the anti-fibrotic effects of 1,7-dihydroxy-3,4,8-trimethoxyxanthone (ZYC-1) on the dimethylnitrosamine (DMN)-induced rat model. ZYC-1 was isolated from Swertia punicea Hemsl and was administrated to DMN-induced rat model. ZYC decreased the hyaluronic acid (HA), type IV collagen (CIV) and hydroxyproline (Hyp) levels and inhibited the expression of α smooth muscle actin (α-SMA) and transforming growth factor beta 1 (TGF-1β)...
2017: PloS One
keyword
keyword
84771
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"